IP Library › Patent Application 10546303

Patent Application

App. No. 10/546,303

Analogues of glp-1

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 10/546,303

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals, and to pharmaceutical compositions useful therefor comprising said analogues.

Claims (2065)

1 . A compound of formula (I),

(R 2 R 3 )-A 7- A 8 -A 9 -A 10 -A 11 -A 12 -A 13 -A 14 -A 15 -A 16 -A 17- A 18 -A 19 -A 20 -A 21 -A 22 -A 23 -A 24 A 25 -A 26 -A 27- A 28 -A 29 -A 30 -A 31 -A 32 -A 33 -A 34 -A 35 -A 36 -A 37- A 38 -A 39 -R 1 , (I)

wherein:

A 7 is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A 3 is Abu, β-Ala, Ser, Gly or Val;

A 9 is Glu, N-Me-Glu, N-Me-Asp or Asp;

A 10 is Gly, Acc, β-Ala or Aib;

A 11 is Thr or Ser;

A 12 is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, 1-Nal, 2-Nal, Cha, Trp or X 1 -Phe;

A 13 is Thr or Ser;

A 14 is Ser or Aib;

A 15 is Asp or Glu;

A 16 is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;

A 17 is Ser or Thr;

A 18 is Ser or Thr;

A 19 is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, 1-Nal, 2-Nal, or X 1 -Phe;

A 20 is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X 1 -Phe;

A 21 is Glu or Asp;

A 22 is Gly, Acc, β-Ala, Glu or Aib;

A 23 is Gin, Asp, Asn or Glu;

A 24 is Ala, Aib, Val, Abu, Tle or Acc;

A 25 is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O) or HN—CH((CH 2 ) e —X 3 )—C(O);

A 26 is Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O) or HN—CH((CH 2 ) e —X 3 C(O);

A 27 is Glu, Asp, Leu, Aib or Lys;

A 28 is Phe, 3-Pal, 4-Pal, 1-Nal, 2-Nal, X 1 -Phe, Aic, Acc, Aib, Cha or Trp;

A 29 is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;

A 30 is Ala, Aib or Acc;

A 31 is Trp, 1-Nal, 2-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;

A 32 is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X 1 -Phe or Ala;

A 33 is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X 1 -Phe;

A 34 is Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O) or HN—CH((CH 2 ) e —X 3 )—C(O);

A 35 is Gly, β-Ala, D-Ala, Gaba, Ava, HN—(CH 2 ) m —C(O), Aib, Acc or a D-amino acid;

A 36 is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O), HN—CH((CH 2 ) e —X 3 )—C(O) or deleted;

A 37 is Gly, β-Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, HN—(CH 2 ) m —C(O), HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O), HN—CH((CH 2 ) n —O(R 10 ))—C(O), a D-amino acid, or deleted;

A 38 is D- or L-Lys, D- or L-Arg, D- or L-hArg, D- or L-Orn, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O), HN—CH((CH 2 ) e —X 3 )—C(O) Ava, Ado, Aec or deleted;

A 39 is D- or L-Lys, D- or L-Arg, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O), Ava, Ado, Aec, or Aun, or is deleted;

X 1 is, independently for each occurrence, selected from the group consisting of (C 1 -C 6 )alkyl, OH and halo;

R 1 is OH, NH 2 , (C 1 -C 30 )alkoxy, or NH—X 2 —CH 2 -Z 0 , wherein X 2 is a (C 1 -C 12 )hydrocarbon moiety, and Z 0 is H, OH, CO 2 H or CONH 2 ;

or —C(O)—NHR 12 , wherein X 4 is, independently for each occurrence, —C(O)—, —NH—C(O)— or —CH 2 —, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive;

each of R 2 and R 3 is independently selected from the group consisting of H, (C 1 -C 30 )alkyl, (C 2 -C 30 )alkenyl, phenyl(C 1 -C 30 )alkyl, naphthyl(C 1 -C 30 )alkyl, hydroxy(C 1 -C 30 )alkyl, hydroxy(C 2 -C 30 )alkenyl, hydroxyphenyl(C 1 -C 30 )alkyl, and hydroxynaphthyl(C 1 -C 30 )alkyl; or one of R 2 and R 3 is (CH 3 ) 2 —N—C═N(CH 3 ) 2 , (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl, C(O)X 5 ,

wherein Y is H, OH or NH 2 ; r is 0 to 4; q is 0 to 4; and X 5 is (C 1 -C 30 )alkyl, (C 2 -C30)alkenyl, phenyl(C 1 -C 30 )alkyl, naphthyl(C 1 -C 30 )alkyl, hydroxy(C 1 -C 30 )alkyl, hydroxy(C 2 -C 30 )alkenyl, hydroxyphenyl(C 1 -C 30 )alkyl or hydroxynaphthyl(C 1 -C 30 )alkyl;

e is, independently for each occurrence, an integer from 1 to 4 inclusive;

m is, independently for each occurrence, an integer from 5 to 24 inclusive;

n is, independently for each occurrence, an integer from 1 to 5, inclusive;

each of R 10 and R 11 is, independently for each occurrence, H, (C 1 -C 30 )alkyl, (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl, —C((NH)(NH 2 )) or

and R 12 and R 13 each is, independently for each occurrence, (C 1 -C 30 )alkyl; provided that:

(i) said compound is not:

(Ser 8, β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO: 779);

(Gly 8 , Aib 35 )hGLP-1(7-36)NH 2 (SEQ ID NO: 780); or

(Gly 3 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO: 781);

(ii) when A 7 is Ura, Paa or Pta, then R 2 and R 3 are deleted; and

(iii) when R 10 is (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl, —C((NH)(NH 2 )) or

then R 11 is H or (C 1 -C 30 )alkyl; or a pharmaceutically acceptable salt thereof.

2 . A compound according to claim 1 , wherein A 11 is Thr; A 13 is Thr; A 15 is Asp; A 17 is Ser; A 18 is Ser; A 21 is Glu; A 23 is Gln or Glu; A 27 is Glu; and A 31 is Trp; or a pharmaceutically acceptable salt thereof.

3 . A compound according to claim 2 , wherein A 9 is Glu, N-Me-Glu or N-Me-Asp; A 12 is Phe, Acc or Aic; A 16 is Val, Acc or Aib; A 19 is Tyr; A 20 is Leu, Acc or Cha; A 24 is Ala, Aib or Acc; A 2 is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O) or HN—CH((CH 2 ) e —X 3 )—C(O); A 28 is Phe; A 29 is Ile or Acc; A 30 is Ala or Aib; A 32 is Leu, Acc or Cha; and A 33 is Val or Acc; or a pharmaceutically acceptable salt thereof.

4 . A compound according to claim 3 , wherein A 10 is Gly; A 12 is Phe, A6c or A5c; A 16 is Val, A6c or A5c; A 20 is Leu, A6c, A5c or Cha; A 22 is Gly, β-Ala or Aib; A 24 is Ala or Aib; A 29 is Ile, A6c or A5c; A 32 is Leu, A6c, A5c or Cha; A 33 is Val, A6c or A5c; A 35 is Aib, β-Ala, Ado, A6c, A5c or Gly; and A 37 is Gly, Aib, β-Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof.

5 . A compound according to claim 4 , wherein X 4 for each occurrence is —C(O)—; e for each occurrence is independently 1 or 2; and R 1 is OH or NH 2 ; or a pharmaceutically acceptable salt thereof.

6 . A compound according to claim 5 , wherein R 2 is H and R 3 is (C 1 -C 30 )alkyl, (C 2 -C 30 )alkenyl, (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl,

or a pharmaceutically acceptable salt thereof.

7 . A compound according to claim 5 , wherein R 10 is (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl or

and R 11 is H; or a pharmaceutically acceptable salt thereof

8 . A compound according to claim 7 , wherein R 10 is (C 4 -C 20 )acyl, (C 4 -C 20 )alkylsulfonyl or

or a pharmaceutically acceptable salt thereof.

9 . A compound according to claim 5 , wherein A 8 is Gly, Ser, or Val; or a pharmaceutically acceptable salt thereof.

10 . A compound according to claim 9 wherein A 8 is Gly or Ser; or a pharmaceutically acceptable salt thereof.

11 . A compound according to claim 10 , wherein said compound is according to the formula:

((N α -Me-His) 7 ,Gly 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.1)

((N α -Me-His) 7 ,Gly 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.2)

((N α -Me-His) 7 ,Gly 8 ,Aib 35 ,Arg 26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.3)

((N α -Me-His) 7 ,Gly 8 ,Arg 26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.4)

(Gly 8 ,A6c 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.5)

(Gly 8 ,A5c 35 )hGLP-1(7-36)NH 2 :

(SEQ ID NO.6)

(Gly 8 ,D-Ala 35 )hGLP-1(7-36)NH 2 ; (SEQ ID NO.7)

(Gly 8 ,Aib 35 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.8)

(Gly 8 ,Aib 35 ,A5c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.9)

(Gly 8 ,Aib 35 ,Glu 23 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.10)

(Gly 8 ,Aib 24,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.11)

(Gly 8 ,Aib 30,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.12)

(Gly 8 ,Aib 25,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.13)

(Gly 8 ,Aib 35 ,A6c 16,20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.14)

(Gly 8 ,Aib 35 ,A6c 16,29,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.15)

(Gly 8 ,Aib 35 ,A6c 20,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.16)

(Gly 8 ,Aib 35 ,A6c 20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.17)

(Gly 8 ,Aib 35 ,Lys 25 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.18)

(Gly 8 ,Aib 24,35 ,A6c 20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.19)

(Gly 8 ,Aib 35 ,A6c 29,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.20)

(Gly 8 ,Aib 24,35 ,A6c 29,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.21)

(Gly 8 ,Aib 35 ,A6c 12 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.22)

(Gly 8 ,Aib 35 ,Cha 20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.23)

(Gly 8 ,Aib 35 ,A6c 33 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.24)

(Gly 8 ,A6c 16,20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.25)

(Gly 8 ,Aib 35 ,β-Ala 22 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.26)

(Gly 8 ,Aib 22,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.27)

(Gly 8 ,Aib 35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.28)

(Gly 8 ,Aib 24,35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.29)

(Gly 8 ,Aib 24,25,35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.30)

(Gly 8 ,Aib 24,25,35 ,A6c 16,20,32 ,Glu 23 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.31)

(Gly 8 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.32)

(Gly 8 ,A5c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.33)

(Gly 8 ,Glu 23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.34)

(Gly 8 ,Aib 24 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.35)

(Gly 8 ,Aib 30 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.36)

(Gly 8 ,Aib 25 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.37)

(Gly 8 ,A6c 16,29,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.38)

(Gly 8 ,A6c 20,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.39)

(Gly 8 ,A6c 20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.40)

(Gly 8 ,Lys 25 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.41)

(Gly 8 ,Aib 24 ,A6c 20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.42)

(Gly 8 ,A6c 29,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.43)

(Gly 8 ,Aib 24 ,A6c 29,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.44)

(Gly 8 ,A6c 12 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.45)

(Gly 8 ,Cha 20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.46)

(Gly 8 ,A6c 33 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.47)

(Gly 8 ,β-Ala 22,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.48)

(Gly 8 ,Aib 22 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.49)

(Gly 8 ,Glu 23 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.50)

(Gly 8 ,Aib 24 ,Glu 23 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.51)

(Gly 8 ,Aib 24 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl),β-Ala 35 )

(SEQ ID NO.52)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24,25 ,Glu 23 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.53)

(Gly 8 ,Aib 24,25 ,A6c 16,20,32 ,Glu 23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.54)

(Gly 8 ,Aib 35 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.55)

(Gly 8 ,Aib 35 ,D-Lys 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.56)

(Gly 8 ,β-Ala 35 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.57)

(Gly 8 ,β-Ala 35 ,D-Lys 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.58)

(Gly 8 ,Aib 35 ,Arg 26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.59)

(Gly 8 ,Arg 26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.60)

(Gly 8 ,Aib 35 ,Arg 25,26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.61)

(Gly 8 ,Arg 25,26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.62)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.63)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH;

(SEQ ID NO.64)

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH;

(SEQ ID NO.65)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl),D-Ala 37 )

(SEQ ID NO.66)

hGLP-1(7-37)OH;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.67)

(Gly 8 ,Aib 35 ,Arg 26,34 ,β-Ala 37 ,Lys 38 (N ε -tetradecanoyl))

(SEQ ID NO.68)

hGLP-1(7-38)OH;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 39 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.69)

(Gly 8 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl),β-Ala 37 )hGLP-1(7-37)OH;

(SEQ ID NO.70)

(Gly 8 ,Aib 37 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH;

(SEQ ID NO.71)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Ado 37 )hGLP-1(7-37)OH;

(SEQ ID NO.72)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Ado 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.73)

(Gly 8 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl),D-Ala 37 )hGLP-1(7-37)OH;

(SEQ ID NO.74)

(Gly 8 ,Aib 37 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.75)

(Gly 8 ,Arg 26,34 ,β-Ala 37 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.76)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.77)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.78)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.79)

(Gly 8 ,Lys 26 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.80)

(Gly 8 ,Lys 26 (N ε -tetradecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.81)

(Gly 8 ,Lys 26 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.82)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.83)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.84)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.85)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -decanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.86)

(Gly 8 ,Aib 35 ,Lys 25 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.87)

(Gly 8 ,Aib 35 ,Lys 25 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.88)

(Gly 8 ,Aib 35 ,Lys 25 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.89)

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.90)

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.91)

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.92)

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.93)

(Gly 8 ,Lys 26 (N ε -octanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.94)

(Gly 8 ,Lys 26 (N ε -tetradecanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.95)

(Gly 8 ,Lys 26 (N ε -hexadecanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.96)

(Gly 8 ,Lys 26 (N ε -decanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.97)

(Gly 8 ,Aib 35 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.98)

(Gly 8 ,Aib 35 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.99)

(Gly 8 ,Aib 35 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.100)

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.101)

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.102)

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.103)

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.104)

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.105)

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.106)

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.107)

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.108)

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.109)

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.110)

(Gly 8 ,Aib 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.111)

(Gly 8 ,Aib 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.112)

(Gly 8 ,Aib 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.113)

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.114)

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.115)

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.116)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.117)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.118)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.119)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.120)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.121)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.122)

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.123)

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.124)

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.125)

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.126)

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.127)

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.128)

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.129)

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.130)

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.131)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.132)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.133)

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.134)

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.135)

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 35 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.136)

(Gly 8 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.137)

(Gly 8 ,Lys 34 (N ε -tetradecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.138)

(Gly 8 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.139)

(Gly 8 ,A6c 32 ,Lys 34 (N e -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.140)

(Gly 8 ,Glu 23 ,Lys 34 (N e -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.141)

(Gly 8 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.142)

(Gly 8 ,Arg 26 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.143)

(Gly 8 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl),(β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.144)

(Gly 8 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.145)

(Gly 8 ,Arg 26 ,Lys 34 (N ε -decanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.146)

(Gly 8 ,Arg 25,26 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.147)

(Gly 8 ,Arg 25,26 ,Lys 34 (N ε -tetradecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.148)

(Gly 8 ,Arg 25,26 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.149)

(Gly 8 ,Arg 25,26 ,Lys 34 (N ε -decanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.150)

(Gly 8 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.151)

(Gly 8 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl),β-Ala 35 )

(SEQ ID NO.152)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )

(SEQ ID NO.153)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.154)

(Gly 8 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.155)

(Gly 8 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.156)

(Gly 8 ,Arg 26 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.157)

(Gly 8 ,Arg 26 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.158)

(Gly 8 ,Arg 26 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.159)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.160)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.161)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.162)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.163)

(Gly 8 ,Lys 25 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.164)

(Gly 8 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl),β-Ala 35 )

(SEQ ID NO.165)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Lys 25 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.166)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.167)

(Gly 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.168)

(Gly 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.169)

(Gly 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.170)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -octanoyl),A6c 32 ,Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.171)

(Gly 8 ,Aib 35 ,Lys 26 (N ε -tetradecanoyl),A6c 32 ,Arg 34 )

(SEQ ID NO.172)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Lys 26 (N ε -hexadecanoyl),A6c 32 ,Arg 34 )

(SEQ ID NO.173)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,A6c 32 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.174)

(Gly 8 ,Aib 35 ,A6c 32 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.175)

(Gly 8 ,Aib 35 ,A6c 32 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.176)

(Gly 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.177)

(Gly 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.178)

(Gly 8 ,Aib 35 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.179)

(Gly 8 ,Aib 35 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.180)

(Gly 8 ,Aib 35 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.181)

(Gly 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.182)

(Gly 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.183)

(Gly 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.184)

(Gly 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.185)

(Gly 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.186)

(Gly 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.187)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.188)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24,35 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.189)

(Gly 8 ,Aib 24,35 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.190)

(Gly 8 ,Aib 24,35 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.191)

(Gly 8 ,Aib 24,35 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.192)

(Gly 8 ,Aib 24,35 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.193)

(Gly 8 ,Aib 24,35 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.194)

(Gly 8 ,Aib 24,35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.195)

(Gly 8 ,Aib 24,35 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.196)

(Gly 8 ,Aib 24,35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.197)

(Gly 8 ,Aib 24,35 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.198)

(Gly 8 ,Aib 35 ,Glu 23 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.199)

(Gly 8 ,Aib 35 ,Glu 23 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.200)

(Gly 8 ,Aib 35 ,Glu 23 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.201)

(Gly 8 ,Aib 35 ,Glu 23 ,Lys 34 (N e -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.202)

(Gly 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.203)

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.204)

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.205)

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.206)

(Gly 8 ,Aib 35 ,Glu 23 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.207)

(Gly 8 ,Aib 35 ,Glu 23 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.208)

(Gly 8 ,Aib 35 ,Glu 23 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.209)

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.210)

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.211)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.212)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 30,35 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.213)

(Gly 8 ,Aib 30,35 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.214)

(Gly 8 ,Aib 30,35 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.215)

(Gly 8 ,Aib 30,35 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.216)

(Gly 8 ,Aib 30,35 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.217)

(Gly 8 ,Aib 30,35 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.218)

(Gly 8 ,Aib 30,35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.219)

(Gly 8 ,Aib 30,35 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.220)

(Gly 8 ,Aib 30,35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.221)

(Gly 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.222)

(Gly 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.223)

(Gly 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.224)

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))

(SEQ ID NO.225)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.226)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.227)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))

(SEQ ID NO.228)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24 ,34,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.229)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.230)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24,30,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))

(SEQ ID NO.231)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24,30,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.232)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 24,30,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.233)

hGLP-1(7-36)NH 2 ;

((N α -HEPES-His) 7 ,Gly 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.234)

((N α -HEPA-His) 7 ,Gly 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.235)

((N α -tetradecanoyl-His) 7 ,Gly 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.236)

((N α -tetradecanoyl-His) 7 ,Gly 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.237)

((N α -tetradecanoyl-His) 7 ,Gly 8 ,Aib 35 ,Arg 26,34 )

(SEQ ID NO.238)

hGLP-1(7-36)NH 2 ;

((N α -tetradecanoyl-His) 7 ,Gly 8 ,Arg 26,34 ,β-Ala 35 )

(SEQ ID NO.239)

hGLP-1(7-36)NH 2 ;

((N α -tetradecanoyl-His) 7 ,Gly 8 ,Aib 35 ,Arg 25,26,34 )

(SEQ ID NO.240)

hGLP-1(7-36)NH 2 ;

((N α -tetradecanoyl-His) 7 ,Gly 8 ,Arg 25,26,34 ,β-Ala 35 )

(SEQ ID NO.241)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Lys 26 (N ε -octanesulfonyl),Arg 34 )

(SEQ ID NO.242)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Lys 26 (N ε -dodecanesulfonyl),Arg 34 )

(SEQ ID NO.243)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Lys 26 (N ε -hexadecanesulfonyl),Arg 34 )

(SEQ ID NO.244)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -octanesulfonyl))

(SEQ ID NO.245)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -dodecanesulfonyl))

(SEQ ID NO.246)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -hexadecanesulfonyl))

(SEQ ID NO.247)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -octanesulfonyl))

(SEQ ID NO.248)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanesulfonyl))

(SEQ ID NO.249)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Asp 26 (1-(4-decylpiperazine)),Arg 34 )

(SEQ ID NO.250)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Asp 26 (1-(4-dodecylpiperazine)),Arg 34 )

(SEQ ID NO.251)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Asp 26 (1-(4-tetradecylpiperazine)),Arg 34 )

(SEQ ID NO.252)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Asp 26 (1-(4-hexadecylpiperazine)),Arg 34 )

(SEQ ID NO.253)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-decylpiperazine)))

(SEQ ID NO.254)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-dodecylpiperazine)))

(SEQ ID NO.255)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.256)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.257)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 36 (1-(4-decylpiperazine)))

(SEQ ID NO.258)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 36 (1-(4-dodecylpiperazine)))

(SEQ ID NO.259)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 36 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.260)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.261)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.262)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.263)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.264)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.265)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.266)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.267)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.268)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-decylpiperazine)))

(SEQ ID NO.269)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-dodecylpiperazine)))

(SEQ ID NO.270)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.271)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.272)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-decylpiperazine)))

(SEQ ID NO.273)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-dodecylpiperazine)))

(SEQ ID NO.274)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.275)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.276)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-decylpiperazine)))

(SEQ ID NO.277)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-dodecylpiperazine)))

(SEQ ID NO.278)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.279)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.280)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.281)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.282)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.283)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.284)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.285)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.286)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.287)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.288)

hGLP-1(7-38)NH 2 ;

Gly 8 ,Aib 35 ,Arg 26,34 ,Glu 36 (1-dodecylamino))

(SEQ ID NO.289)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Glu 26 (1-dodecylamino),Arg 34 )

(SEQ ID NO.290)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Glu 34 (1-dodecylamino))

(SEQ ID NO.291)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Glu 38 (1-dodecylamino))

(SEQ ID NO.292)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.293)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.294)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.295)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.296)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.297)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl))

(SEQ ID NO.298)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.299)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.300)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.301)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.302)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.303)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.304)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.305)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.306)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.307)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.308)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.309)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.310)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.311)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.312)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.313)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.314)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.315)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.316)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.317)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.318)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.319)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.320)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg2526,34,Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.321)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.322)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.323)

hGLP-1(7-36)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.324)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.325)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.326)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.327)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.328)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.329)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.330)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.331)

hGLP-1(7-38)NH 2 ;

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.332)

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.333)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Ava 37 ,Ado 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.334)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 37 ,Ava 38 ,Ado 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.335)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Aun 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.336)

(Gly 8 ,Aib 17,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.337)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,D-Asp 37 ,Ava 38 ,Aun 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.338)

(Gly 8 ,Glu 22,23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.339)

(Gly 8 ,Lys 18 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.340)

(Gly 8 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.341)

(Gly 8 ,Lys 33 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.342)

(Gly 8 ,Lys 18 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.343)

(Gly 8 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.344)

(Gly 8 ,β-Ala 35 ,D-Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.345)

(Gly 8 ,Aib 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.346)

(Gly 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.347)

(Gly 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38,39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.348)

(Gly 8 ,Lys 18 ,27,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.349)

(Gly 8 ,Lys 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.350)

(Gly 8 ,β-Ala 35 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.351)

(Gly 8 ,Arg 26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.352)

(Gly 8 ,D-Arg 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.353)

(Gly 8 ,β-Ala 35 ,Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.354)

(Gly 8 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.355)

(Gly 8 ,Aib 35 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.356)

(Gly 8 ,Aib 35 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.357)

(Gly 8 ,Aib 35 ,2-Nal 28,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.358)

(Gly 8 ,Aib 35 ,Arg 26,34 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.359)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.360)

(Gly 8 ,Aib 35 ,2-Nal 19,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.361)

(Gly 8 ,Aib 35 ,2-Nal 12,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.362)

(Gly 8 ,Aib 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.363)

(Gly 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.364)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -dodecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.365)

(Gly 8 ,β-Ala 35 ,Ser 37 (O-decanoyl))hGLP1(7-37)-NH 2 ;

(SEQ ID NO.366)

(Gly 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 ,Lys 39 (N ε -octanoyl))hGLP-1(7-39)NH 2 ;

(SEQ ID NO.367)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -octanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.368)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -decanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.369)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -tetradecanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.370)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -dodecanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.371)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -dodecanoyl))hGLP-1(8-37)NH 2 ;

(SEQ ID NO.372)

(Gly 8 ,Arg 26 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.373)

(Gly 8 ,Arg 26 ,Phe 31 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.374)

(Gly 8 ,Arg 26 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.375)

(Gly 8 ,Arg 26 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.376)

(Gly 8 ,Arg 26,34 ,Phe 31 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.377)

(Gly 8 ,Arg 26,34 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.378)

(Gly 8 ,Arg 34 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.379)

(Gly 8 ,Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.380)

(Gly 8 ,Phe 31 ,Arg 34 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.381)

(Gly 8 ,Phe 31 ,Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.382)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -Aec-decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.383)

(Gly 8 ,β-Ala 35 ,Ser 37 (O-decanoyl))hGLP1(7-37)-NH 2 ;

(SEQ ID NO.384)

or a pharmaceutically acceptable salt thereof.

12 . A compound according to claim 10 , wherein said compound is according to the formula:

((N α -Me-His) 7 ,Ser 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.385)

((N α -Me-His) 7 ,Ser 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.386)

((N α -Me-His) 7 ,Ser 8 ,Aib 35 ,Arg 26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.387)

((N α -Me-His) 7 ,Ser 8 ,Arg 26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.388)

(Ser 8 ,A6c 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.389)

(Ser 8 ,A5c 35 )hGLP-1(7-36)NH 2 :

(SEQ ID NO.390)

(Ser 8 ,D-Ala 35 )hGLP-1(7-36)NH 2 ; (SEQ ID NO.391)

(Ser 8 ,Aib 35 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.392)

(Ser 8 ,Aib 35 ,A5c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.393)

(Ser 8 ,Aib 35 ,Glu 23 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.394)

(Ser 8 ,Aib 24,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.395)

(Ser 8 ,Aib 30,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.396)

(Ser 8 ,Aib 25,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.397)

(Ser 8 ,Aib 35 ,A6c 16,20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.398)

(Ser 8 ,Aib 35 ,A6c 16,29,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.399)

(Ser 8 ,Aib 35 ,A6c 20,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.400)

(Ser 8 ,Aib 35 ,A6c 20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.401)

(Ser 8 ,Aib 35 ,Lys 25 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.402)

(Ser 8 ,Aib 24,35 ,A6c 20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.403)

(Ser 8 ,Aib 35 ,A6c 29,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.404)

(Ser 8 ,Aib 24,35 ,A6c 29,32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.405)

(Ser 8 ,Aib 35 ,A6c 12 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.406)

(Ser 8 ,Aib 35 ,Cha 20 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.407)

(Ser 8 ,Aib 35 ,A6c 33 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.408)

(Ser 8 ,A6c 16,20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.409)

(Ser 8 ,Aib 35 ,β-Ala 22 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.410)

(Ser 8 ,Aib 22,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.411)

(Ser 8 ,Aib 35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.412)

(Ser 8 ,Aib 24,35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.413)

(Ser 8 ,Aib 24,25,35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.414)

(Ser 8 ,Aib 24,25,35 ,A6c 16,20,32 ,Glu 23 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.415)

(Ser 8 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.416)

(Ser 8 ,A5c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.417)

(Ser 8 ,Glu 23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.418)

(Ser 8 ,Aib 24 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.419)

(Ser 8 ,Aib 30 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.420)

(Ser 8 ,Aib 25 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.421)

(Ser 8 ,A6c 16,29,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.422)

(Ser 8 ,A6c 20,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.423)

(Ser 8 ,A6c 20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.424)

(Ser 8 ,Lys 25 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.425)

(Ser 8 ,Aib 24 ,A6c 20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.426)

(Ser 8 ,A6c 29,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.427)

(Ser 8 ,Aib 24 ,A6c 29,32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.428)

(Ser 8 ,A6c 12 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.429)

(Ser 8 ,Cha 20 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.430)

(Ser 8 ,A6c 33 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.431)

(Ser 8 ,β-Ala 22,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.432)

(Ser 8 ,Aib 22 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.433)

(Ser 8 ,Glu 23 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.434)

(Ser 8 ,Aib 24 ,Glu 23 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.435)

(Ser 8 ,Aib 24 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl),β-Ala 35 )

(SEQ ID NO.436)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24,25 ,Glu 23 ,A6c 32 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.437)

(Ser 8 ,Aib 24,25 ,A6c 16,20,32 ,Glu 23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.438)

(Ser 8 ,Aib 35 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.439)

(Ser 8 ,Aib 35 ,D-Lys 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.440)

(Ser 8 ,β-Ala 35 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.441)

(Ser 8 ,β-Ala 35 ,D-Lys 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.442)

(Ser 8 ,Aib 35 ,Arg 26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.443)

(Ser 8 ,Arg 26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.444)

(Ser 8 ,Aib 35 ,Arg 25,26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.445)

(Ser 8 ,Arg 25,26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.446)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.447)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH;

(SEQ ID NO.448)

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH;

(SEQ ID NO.449)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl),D-Ala 37 )

(SEQ ID NO.450)

hGLP-1(7-37)OH;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.451)

(Ser 8 ,Aib 35 ,Arg 26,34 ,β-Ala 37 ,Lys 38 (N ε -tetradecanoyl))

(SEQ ID NO.452)

hGLP-1(7-38)OH;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 39 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.453)

(Ser 8 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl),β-Ala 37 )hGLP-1(7-37)OH;

(SEQ ID NO.454)

(Ser 8 ,Aib 37 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH;

(SEQ ID NO.455)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Ado 37 )hGLP-1(7-37)OH;

(SEQ ID NO.456)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Ado 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.457)

(Ser 8 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl),D-Ala 37 )hGLP-1(7-37)OH;

(SEQ ID NO.458)

(Ser 8 ,Aib 37 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.459)

(Ser 8 ,Arg 26,34 ,β-Ala 37 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH;

(SEQ ID NO.460)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.461)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.462)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.463)

(Ser 8 ,Lys 26 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.464)

(Ser 8 ,Lys 26 (N ε -tetradecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.465)

(Ser 8 ,Lys 26 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.466)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.467)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.468)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.469)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -decanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.470)

(Ser 8 ,Aib 35 ,Lys 25 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.471)

(Ser 8 ,Aib 35 ,Lys 25 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.472)

(Ser 8 ,Aib 35 ,Lys 25 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.473)

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.474)

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.475)

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.476)

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.477)

(Ser 8 ,Lys 26 (N ε -octanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.478)

(Ser 8 ,Lys 26 (N ε -tetradecanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.479)

(Ser 8 ,Lys 26 (N ε -hexadecanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.480)

(Ser 8 ,Lys 26 (N ε -decanoyl),Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.481)

(Ser 8 ,Aib 35 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.482)

(Ser 8 ,Aib 35 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.483)

(Ser 8 ,Aib 35 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.484)

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.485)

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.486)

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.487)

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.488)

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.489)

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.490)

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.491)

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.492)

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.493)

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.494)

(Ser 8 ,Aib 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.495)

(Ser 8 ,Aib 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.496)

(Ser 8 ,Aib 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.497)

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.498)

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.499)

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.500)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.501)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.502)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.503)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.504)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.505)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.506)

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.507)

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.508)

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.509)

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.510)

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.511)

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.512)

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ;

(SEQ ID NO.513)

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.514)

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.515)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.516)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.517)

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.518)

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.519)

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 35 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.520)

(Ser 8 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.521)

(Ser 8 ,Lys 34 (N ε -tetradecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.522)

(Ser 8 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.523)

(Ser 8 ,A6c 32 ,Lys 34 (N e -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.524)

(Ser 8 ,Glu 23 ,Lys 34 (N e -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.525)

(Ser 8 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.526)

(Ser 8 ,Arg 26 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.527)

(Ser 8 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl),(β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.528)

(Ser 8 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.529)

(Ser 8 ,Arg 26 ,Lys 34 (N ε -decanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.530)

(Ser 8 ,Arg 25,26 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.531)

(Ser 8 ,Arg 25,26 ,Lys 34 (N ε -tetradecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.532)

(Ser 8 ,Arg 25,26 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.533)

(Ser 8 ,Arg 25,26 ,Lys 34 (N ε -decanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.534)

(Ser 8 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -octanoyl),β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.535)

(Ser 8 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl),β-Ala 35 )

(SEQ ID NO.536)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Lys 25 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl),β-Ala 35 )

(SEQ ID NO.537)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.538)

(Ser 8 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.539)

(Ser 8 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.540)

(Ser 8 ,Arg 26 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.541)

(Ser 8 ,Arg 26 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.542)

(Ser 8 ,Arg 26 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.543)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.544)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.545)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.546)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.547)

(Ser 8 ,Lys 25 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.548)

(Ser 8 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl),β-Ala 35 )

(SEQ ID NO.549)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Lys 25 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.550)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.551)

(Ser 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.552)

(Ser 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.553)

(Ser 8 ,Arg 25,26,34 ,β-Ala 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.554)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -octanoyl),A6c 32 ,Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.555)

(Ser 8 ,Aib 35 ,Lys 26 (N ε -tetradecanoyl),A6c 32 ,Arg 34 )

(SEQ ID NO.556)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Lys 26 (N ε -hexadecanoyl),A6c 32 ,Arg 34 )

(SEQ ID NO.557)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,A6c 32 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.558)

(Ser 8 ,Aib 35 ,A6c 32 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.559)

(Ser 8 ,Aib 35 ,A6c 32 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.560)

(Ser 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.561)

(Ser 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.562)

(Ser 8 ,Aib 35 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.563)

(Ser 8 ,Aib 35 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.564)

(Ser 8 ,Aib 35 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.565)

(Ser 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.566)

(Ser 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.567)

(Ser 8 ,Aib 35 ,Arg 26 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.568)

(Ser 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.569)

(Ser 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.570)

(Ser 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.571)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.572)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24,35 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.573)

(Ser 8 ,Aib 24,35 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.574)

(Ser 8 ,Aib 24,35 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.575)

(Ser 8 ,Aib 24,35 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.576)

(Ser 8 ,Aib 24,35 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.577)

(Ser 8 ,Aib 24,35 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.578)

(Ser 8 ,Aib 24,35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.579)

(Ser 8 ,Aib 24,35 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.580)

(Ser 8 ,Aib 24,35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.581)

(Ser 8 ,Aib 24,35 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.582)

(Ser 8 ,Aib 35 ,Glu 23 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.583)

(Ser 8 ,Aib 35 ,Glu 23 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.584)

(Ser 8 ,Aib 35 ,Glu 23 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.585)

(Ser 8 ,Aib 35 ,Glu 23 ,Lys 34 (N e -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.586)

(Ser 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 34 (N e -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.587)

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.588)

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.589)

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.590)

(Ser 8 ,Aib 35 ,Glu 23 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.591)

(Ser 8 ,Aib 35 ,Glu 23 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.592)

(Ser 8 ,Aib 35 ,Glu 23 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.593)

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.594)

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.595)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.596)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 30,35 ,Lys 26 (N ε -octanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.597)

(Ser 8 ,Aib 30,35 ,Lys 26 (N ε -tetradecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.598)

(Ser 8 ,Aib 30,35 ,Lys 26 (N ε -hexadecanoyl),Arg 34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.599)

(Ser 8 ,Aib 30,35 ,Arg 26 ,Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.600)

(Ser 8 ,Aib 30,35 ,Arg 26 ,Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.601)

(Ser 8 ,Aib 30,35 ,Arg 26 ,Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.602)

(Ser 8 ,Aib 30,35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.603)

(Ser 8 ,Aib 30,35 ,Arg 26,34 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.604)

(Ser 8 ,Aib 30,35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.605)

(Ser 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.606)

(Ser 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.607)

(Ser 8 ,Aib 35 ,Glu 23 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.608)

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))

(SEQ ID NO.609)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.610)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.611)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))

(SEQ ID NO.612)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24 ,34,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.613)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.614)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24,30,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -octanoyl))

(SEQ ID NO.615)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24,30,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -tetradecanoyl))

(SEQ ID NO.616)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 24,30,35 ,Glu 23 ,Arg 26,34 ,A6c 32 ,Lys 36 (N ε -hexadecanoyl))

(SEQ ID NO.617)

hGLP-1(7-36)NH 2 ;

((N α -HEPES-His) 7 ,Ser 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.618)

((N α -HEPA-His) 7 ,Ser 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.619)

((N α -tetradecanoyl-His) 7 ,Ser 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.620)

((N α -tetradecanoyl-His) 7 ,Ser 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.621)

((N α -tetradecanoyl-His) 7 ,Ser 8 ,Aib 35 ,Arg 26,34 )

(SEQ ID NO.622)

hGLP-1(7-36)NH 2 ;

((N α -tetradecanoyl-His) 7 ,Ser 8 ,Arg 26,34 ,β-Ala 35 )

(SEQ ID NO.623)

hGLP-1(7-36)NH 2 ;

((N α -tetradecanoyl-His) 7 ,Ser 8 ,Aib 35 ,Arg 25,26,34 )

(SEQ ID NO.624)

hGLP-1(7-36)NH 2 ;

((N α -tetradecanoyl-His) 7 ,Ser 8 ,Arg 25,26,34 ,β-Ala 35 )

(SEQ ID NO.625)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Lys 26 (N ε -octanesulfonyl),Arg 34 )

(SEQ ID NO.626)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Lys 26 (N ε -dodecanesulfonyl),Arg 34 )

(SEQ ID NO.627)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Lys 26 (N ε -hexadecanesulfonyl),Arg 34 )

(SEQ ID NO.628)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -octanesulfonyl))

(SEQ ID NO.629)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -dodecanesulfonyl))

(SEQ ID NO.630)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -hexadecanesulfonyl))

(SEQ ID NO.631)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -octanesulfonyl))

(SEQ ID NO.632)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -hexadecanesulfonyl))

(SEQ ID NO.633)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Asp 26 (1-(4-decylpiperazine)),Arg 34 )

(SEQ ID NO.634)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Asp 26 (1-(4-dodecylpiperazine)),Arg 34 )

(SEQ ID NO.635)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Asp 26 (1-(4-tetradecylpiperazine)),Arg 34 )

(SEQ ID NO.636)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Asp 26 (1-(4-hexadecylpiperazine)),Arg 34 )

(SEQ ID NO.637)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-decylpiperazine)))

(SEQ ID NO.638)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-dodecylpiperazine)))

(SEQ ID NO.639)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.640)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Asp 34 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.641)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 36 (1-(4-decylpiperazine)))

(SEQ ID NO.642)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 36 (1-(4-dodecylpiperazine)))

(SEQ ID NO.643)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 36 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.644)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.645)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.646)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.647)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.648)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.649)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.650)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.651)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.652)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-decylpiperazine)))

(SEQ ID NO.653)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-dodecylpiperazine)))

(SEQ ID NO.654)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.655)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Asp 26 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.656)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-decylpiperazine)))

(SEQ ID NO.657)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-dodecylpiperazine)))

(SEQ ID NO.658)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.659)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Asp 34 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.660)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-decylpiperazine)))

(SEQ ID NO.661)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-dodecylpiperazine)))

(SEQ ID NO.662)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.663)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 36 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.664)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.665)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.666)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.667)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.668)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-decylpiperazine)))

(SEQ ID NO.669)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-dodecylpiperazine)))

(SEQ ID NO.670)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-tetradecylpiperazine)))

(SEQ ID NO.671)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Asp 38 (1-(4-hexadecylpiperazine)))

(SEQ ID NO.672)

hGLP-1(7-38)NH 2 ;

Ser 8 ,Aib 35 ,Arg 26,34 ,Glu 36 (1-dodecylamino))

(SEQ ID NO.673)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Glu 26 (1-dodecylamino),Arg 34 )

(SEQ ID NO.674)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Glu 34 (1-dodecylamino))

(SEQ ID NO.675)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Glu 38 (1-dodecylamino))

(SEQ ID NO.676)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.677)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.678)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.679)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.680)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.681)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl))

(SEQ ID NO.682)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.683)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26 ,Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.684)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.685)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.686)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.687)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.688)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.689)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.690)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.691)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.692)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.693)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.694)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.695)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.696)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.697)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.698)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,34 ,Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.699)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.700)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.701)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.702)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26 ,Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.703)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.704)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg2526,34,Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.705)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.706)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.707)

hGLP-1(7-36)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.708)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.709)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.710)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.711)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))

(SEQ ID NO.712)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))

(SEQ ID NO.713)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))

(SEQ ID NO.714)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35,37 ,Arg 25,26,34 ,Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))

(SEQ ID NO.715)

hGLP-1(7-38)NH 2 ;

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.716)

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.717)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Ava 37 ,Ado 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.718)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 37 ,Ava 38 ,Ado 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.719)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Aun 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.720)

(Ser 8 ,Aib 17,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.721)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,D-Asp 37 ,Ava 38 ,Aun 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.722)

(Ser 8 ,Glu 22,23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.723)

(Ser 8 ,Lys 18 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.724)

(Ser 8 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.725)

(Ser 8 ,Lys 33 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.726)

(Ser 8 ,Lys 18 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.727)

(Ser 8 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.728)

(Ser 8 ,β-Ala 35 ,D-Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.729)

(Ser 8 ,Aib 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.730)

(Ser 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.731)

(Ser 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38,39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.732)

(Ser 8 ,Lys 18 ,27,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.733)

(Ser 8 ,Lys 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.734)

(Ser 8 ,β-Ala 35 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.735)

(Ser 8 ,Arg 26,34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.736)

(Ser 8 ,D-Arg 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.737)

(Ser 8 ,β-Ala 35 ,Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.738)

(Ser 8 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.739)

(Ser 8 ,Aib 35 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.740)

(Ser 8 ,Aib 35 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.741)

(Ser 8 ,Aib 35 ,2-Nal 28,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.742)

(Ser 8 ,Aib 35 ,Arg 26,34 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.743)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.744)

(Ser 8 ,Aib 35 ,2-Nal 19,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.745)

(Ser 8 ,Aib 35 ,2-Nal 12,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.746)

(Ser 8 ,Aib 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.747)

(Ser 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.748)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -dodecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.749)

(Ser 8 ,β-Ala 35 ,Ser 37 (O-decanoyl))hGLP1(7-37)-NH 2 ;

(SEQ ID NO.750)

(Ser 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 ,Lys 39 (N ε -octanoyl))hGLP-1(7-39)NH 2 ;

(SEQ ID NO.751)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -octanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.752)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -decanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.753)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -tetradecanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.754)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -dodecanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.755)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -dodecanoyl))hGLP-1(8-37)NH 2 ;

(SEQ ID NO.756)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -Aec-decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.757)

(Ser 8 ,Arg 26 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.758)

(Ser 8 ,Arg 26 ,Phe 31 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.759)

(Ser 8 ,Arg 26 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.760)

(Ser 8 ,Arg 26 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.761)

(Ser 8 ,Arg 26,34 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.762)

(Ser 8 ,Arg 34 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.763)

(Ser 8 ,Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.764)

(Ser 8 ,Phe 31 ,Arg 34 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.765)

(Ser 8 ,Phe 31 ,Arg 34 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.766)

or a pharmaceutically acceptable salt thereof.

13 . A compound according to claim 11 wherein said compound is:

(Gly 8 ,Aib 35 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.8)

(Gly 8 ,Aib 35 ,Glu 23 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.10)

(Gly 8 ,Aib 24,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.11)

(Gly 8 ,Aib 35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.28)

(Gly 8 ,Glu 23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.34)

(Gly 8 ,Aib 35 ,Arg 26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.59)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.117)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.332)

(Gly 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.333)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -Aec-decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.383)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Ava 37 ,Ado 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.334)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Asp 37 ,Ava 35 ,Ado 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.335)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Aun 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.336)

(Gly 8 ,Aib 17,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.337)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,D-Asp 37 ,Ava 38 ,Aun 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.338)

(Gly 8 ,Glu 22,23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.339)

(Gly 8 ,Lys 18 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.340)

(Gly 8 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.341)

(Gly 8 ,Lys 33 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.342)

(Gly 8 ,Lys 18 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.343)

(Gly 8 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.344)

(Gly 8 ,β-Ala 35 ,D-Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.345)

(Gly 8 ,Aib 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.346)

(Gly 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.347)

(Gly 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38,39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.348)

(Gly 8 ,Lys 18,27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.349)

(Gly 8 ,Lys 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.350)

(Gly 8 ,β-Ala 35 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.351)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,)hGLP-1(7-36)NH 2 ;

(SEQ ID NO.352)

(Gly 8 ,D-Arg 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.353)

(Gly 8 ,β-Ala 35 ,Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.354)

(Gly 8 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.355)

(Gly 8 ,Aib 35 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.356)

(Gly 8 ,Aib 35 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.357)

(Gly 8 ,Aib 35 ,2-Nal 28,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.358)

(Gly 8 ,Aib 35 ,Arg 26,34 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.359)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.360)

(Gly 8 ,Aib 35 ,2-Nal 19,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.361)

(Gly 8 ,Aib 35 ,2-Nal 12,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.362)

(Gly 8 ,Aib 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36) NH 2 ;

(SEQ ID NO.99)

(Gly 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.364)

(Gly 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -dodecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.365)

(Gly 8 ,β-Ala 35 ,Ser 37 (O-decanoyl))hGLP1(7-37)-NH 2 ;

(SEQ ID NO.384)

(Gly 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 ,Lys 39 (N ε -octanoyl))hGLP-1(7-39)NH 2 ;

(SEQ ID NO.367)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -octanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.368)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -decanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.369)

(Gly 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -tetradecanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.370)

or a pharmaceutically acceptable salt thereof.

14 . A compound according to claim 12 wherein said compound is:

(Ser 8 ,Aib 35 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.392)

(Ser 8 ,Aib 35 ,Glu 23 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.394)

(Ser 8 ,Aib 24,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.395)

(Ser 8 ,Aib 35 ,Glu 23 ,A6c 32 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.412)

(Ser 8 ,Glu 23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.418)

(Ser 8 ,Aib 35 ,Arg 26,34 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.443)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.501)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.716)

(Ser 8 ,Aib 35 ,Lys 25 ,Arg 26,34 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH;

(SEQ ID NO.717)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 36 (N ε -Aec-decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.757)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Ava 37 ,Ado 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.718)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Asp 37 ,Ava 35 ,Ado 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.719)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Aun 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.720)

(Ser 8 ,Aib 17,35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.389)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,D-Asp 37 ,Ava 38 ,Aun 39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.722)

(Ser 8 ,Glu 22,23 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.723)

(Ser 8 ,Lys 18 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.724)

(Ser 8 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.725)

(Ser 8 ,Lys 33 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.726)

(Ser 8 ,Lys 18 ,Leu 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.727)

(Ser 8 ,D-Arg 36 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.728)

(Ser 8 ,β-Ala 35 ,D-Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.729)

(Ser 8 ,Aib 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.730)

(Ser 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.731)

(Ser 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38,39 )hGLP-1(7-39)NH 2 ;

(SEQ ID NO.732)

(Ser 8 ,Lys 18,27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.733)

(Ser 8 ,Lys 27 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.734)

(Ser 8 ,β-Ala 35 ,Arg 38 )hGLP-1(7-38)NH 2 ;

(SEQ ID NO.735)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,)hGLP-1(7-36)NH 2 ;

(SEQ ID NO.736)

(Ser 8 ,D-Arg 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.737)

(Ser 8 ,β-Ala 35 ,Arg 37 )hGLP-1(7-37)NH 2 ;

(SEQ ID NO.738)

(Ser 8 ,Phe 31 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.739)

(Ser 8 ,Aib 35 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.740)

(Ser 8 ,Aib 35 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.741)

(Ser 8 ,Aib 35 ,2-Nal 28,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.742)

(Ser 8 ,Aib 35 ,Arg 26,34 ,2-Nal 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.743)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Phe 31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.744)

(Ser 8 ,Aib 35 ,2-Nal 19,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.745)

(Ser 8 ,Aib 35 ,2-Nal 12,31 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.746)

(Ser 8 ,Aib 35 ,Lys 36 (N ε -decanoyl))hGLP-1(7-36) NH 2 ;

(SEQ ID NO.483)

(Ser 8 ,Aib 35 ,Arg 34 ,Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.748)

(Ser 8 ,Aib 35 ,Arg 26,34 ,Lys 36 (N ε -dodecanoyl))hGLP-1(7-36)NH 2 ;

(SEQ ID NO.749)

(Ser 8 ,β-Ala 35 ,Ser 37 (O-decanoyl))hGLP1(7-37)-NH 2 ;

(SEQ ID NO.539)

(Ser 8 ,Aib 27 ,β-Ala 35,37 ,Arg 38 ,Lys 39 (N ε -octanoyl))hGLP-1(7-39)NH 2 ;

(SEQ ID NO.751)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -octanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.752)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -decanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID.NO.753)

(Ser 8 ,Arg 26,34 ,β-Ala 35 ,Lys 37 (N ε -tetradecanoyl))hGLP-1(7-37)NH 2 ;

(SEQ ID NO.754)

or a pharmaceutically acceptable salt thereof.

15 . A compound according to claim 1 , wherein said compound is:

Ser 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.767)

(Abu 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.768)

(Val 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.769)

(β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.770)

(Abu 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.771)

(Val 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.772)

(β-Ala 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.773)

or a pharmaceutically acceptable salt thereof.

16 . A compound according to claim 15 , wherein said compound is:

Ser 8 , Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.767)

(Abu 8 ,β-Ala 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.768)

(Abu 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.771)

or a pharmaceutically acceptable salt thereof.

17 . A compound according to claim 16 , wherein said compound is:

Ser 8 ,Aib 35 )hGLP-1(7-36)NH 2 ;

(SEQ ID NO.767)

or a pharmaceutically acceptable salt thereof.

18 . A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

19 . A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

20 . A method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

21 . A method according to claim 20 wherein said disease is Type I diabetes or Type II diabetes.

Assignments (5)

CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED ON REEL 296336 FRAME 0777. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 5, 2016

From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.

To: IPSEN PHARMA S.A.S.

Reel/Frame 037430/0194 →

CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS PREVIOUSLY RECORDED ON REEL 023034 FRAME 0251. ASSIGNOR(S) HEREBY CONFIRMS THE ADDRESS SHOULD BE 65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT, FRANCE. Recorded Jan 16, 2013

From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.)

To: IPSEN PHARMA S.A.S.

Reel/Frame 029636/0777 →

CHANGE OF NAME Recorded Jul 31, 2009

From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.)

To: IPSEN PHARMA S.A.S.

Reel/Frame 023034/0251 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2006

From: BIOMEASURE, INCORPORATED

To: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.

Reel/Frame 017987/0534 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2005

From: DONG, ZHENG XIN

To: BIOMEASURE, INCORPORATED

Reel/Frame 017269/0319 →